Matthew Sykes
Stock Analyst at Goldman Sachs
(3.87)
# 605
Out of 4,877 analysts
205
Total ratings
52.82%
Success rate
7.8%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $4.94 | +1.21% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $3.40 | -11.76% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $11.58 | -43.87% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $41.20 | +9.22% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.31 | +50.80% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $36.79 | +30.47% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $11.12 | +52.88% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $145.45 | +10.00% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.31 | +36.80% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $96.72 | +29.24% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $13.46 | +4.01% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $197.54 | +21.49% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $19.54 | +33.06% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $151.73 | +12.04% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $52.04 | +7.61% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $92.31 | -13.34% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.24 | +20.97% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $168.94 | +12.47% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.72 | +141.41% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.41 | +76.35% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $27.03 | +36.88% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $53.14 | +22.32% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $157.59 | +58.64% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.65 | +260.90% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,174.72 | +10.66% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $11.25 | +6.67% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $405.46 | +57.85% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $118.01 | +22.87% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.06 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $4.94
Upside: +1.21%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $3.40
Upside: -11.76%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $11.58
Upside: -43.87%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $41.20
Upside: +9.22%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.31
Upside: +50.80%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $36.79
Upside: +30.47%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $11.12
Upside: +52.88%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $145.45
Upside: +10.00%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.31
Upside: +36.80%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $96.72
Upside: +29.24%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $13.46
Upside: +4.01%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $197.54
Upside: +21.49%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $19.54
Upside: +33.06%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $151.73
Upside: +12.04%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $52.04
Upside: +7.61%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $92.31
Upside: -13.34%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.24
Upside: +20.97%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $168.94
Upside: +12.47%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.72
Upside: +141.41%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.41
Upside: +76.35%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $27.03
Upside: +36.88%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $53.14
Upside: +22.32%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $157.59
Upside: +58.64%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.65
Upside: +260.90%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,174.72
Upside: +10.66%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $11.25
Upside: +6.67%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $405.46
Upside: +57.85%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $118.01
Upside: +22.87%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $48.06
Upside: -